B04 Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study.
Authors
Melisi, DSiveke, J
Blanc, J
Von Hoff, D
Wang-Gillam, A
Chen, L
Becker, C
Mamlouk, K
De Jong, F
Hubner, Richard A
Affiliation
Università di Verona, VeronaIssue Date
2016-09-21
Metadata
Show full item recordCitation
B04 Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study. 2016, 27 (suppl_4): iv18 Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw333.04Additional Links
https://academic.oup.com/annonc/article/27/suppl_4/iv18/2770148/B04Effects-of-nanoliposomal-irinotecan-nal-IRI-MMType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw333.04